PROTAC PARP1 degrader-5
PROTAC PARP1 degrader-5 is a PARP1 PROTAC degrader with a DC50 of 0.12 μM. PROTAC PARP1 degrader-5 hijacks the ubiquitin-proteasome system via catalytic ternary complex formation to drive sustained PARP1 degradation. PROTAC PARP1 degrader-5 induces DNA damage, drives marginal cytosolic double-stranded DNA accumulation in tumor cells, and up-regulates PD-L1 surface expression in tumor cells. PROTAC PARP1 degrader-5 shows tumor growth inhibition activity in murine melanoma models when encapsulated in lipid nanoparticles. PROTAC PARP1 degrader-5 can be used for the research of cancer, such as melanoma.
(Pink: PARP-1 ligand (HY-10162); Blue: VHL ligand (HY-112078); Black: linker (HY-W012241)).
For research use only. We do not sell to patients.
- Formula: C55H69FN8O7S
- Molecular Weight:1005.25
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
VHL |
PARP1 0.12 μM (DC50) |
In Vitro
PROTAC PARP1 degrader-5 (Compound PROP) (0.01-25 μM; 12-24 h) potently degrades PARP1 protein in B16F10 cells with a DC50 of 0.12 μM[1].
PROTAC PARP1 degrader-5 (1 μM; 24 h) reduces PARP1 fluorescence intensity in B16F10 cells[1].
PROTAC PARP1 degrader-5 (1 μM; 24 h) induces minimal DNA damage and induces a 3.7-fold increase in cytosolic dsDNA levels in B16F10 cells[1].
PROTAC PARP1 degrader-5 (1 μM; 12 h) up-regulates PD-L1 expression in B16F10, 4T1, H22, KPC, and CT26 cells, causing a 1.7-fold increase in B16F10 cells[1].
PROTAC PARP1 degrader-5 (1 μM) increases the proportion of mature BMDCs to 41.9%[1].
PROTAC PARP1 degrader-5 (1 μM; 24 h) induces cGAMP production in co-cultured DC2.4 and THP-1 cells[1].
PROTAC PARP1 degrader-5 (The lipid nanoparticle-encapsulated PROP) (0.01-25 μM; 24 h) exhibits cytotoxicity in H22 and CT26 cells with IC50 values of 18.6 μM and 13.1 μM, respectively and educes colony-forming[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:B16F10
-
Concentration:0.01, 0.1, 1, 10, 25 μM
-
Incubation Time:12 h; 24 h
-
Result:Induced PARP1 protein degradation with a half-maximal degradation concentration of 0.12 μM.
Reduced PARP1 protein levels to 21.8% of PBS-treated controls after 24 h of treatment.
-
Cell Line:B16F10
-
Concentration:1 μM
-
Incubation Time:24 h
-
Result:Resulted in a marked reduction of PARP1-specific fluorescence signals compared to PBS-treated controls.
In Vivo
PROTAC PARP1 degrader-5 (The lipid nanoparticle-encapsulated PROP) (12 mg/kg; i.v.; daily; 5 days) fails to robustly suppress CT26 colon carcinoma and 4T1 breast cancer growth in female BALB/cJ mice compared to the combination formulation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (female, 6 to 8 weeks old, subcutaneous injection B16F10 cells)[1]
-
Dosage:10 mg/kg (delivered via LNP@PROₚ formulation)
-
Administration:i.v.; daily; 5 consecutive days
-
Result:Delayed tumor growth but did not achieve robust suppression compared to combination formulation.
Extended median survival to up to 40 days, with no mice surviving to 60 days.
Induced a 1.3±0.2-fold up-regulation of PD-L1 in tumor tissue versus PBS controls.
Inhibited lung metastasis
Chemical Information
-
Molecular Weight 1005.25
-
Formula C55H69FN8O7S
-
SMILES
O=C(N[C@@H](C(C)(C)C)C(N1C[C@@H](C[C@H]1C(N[C@H](C2=CC=C(C=C2)C3=C(N=CS3)C)C)=O)O)=O)CCCCCCCCCCC(N4CCN(C(C5=C(F)C=CC(CC6=NNC(C7=C6C=CC=C7)=O)=C5)=O)CC4)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)